a Department of Biomedical Sciences , Seoul National University College of Medicine , Yongon-Dong, Seoul 110-799 , Korea.
b Department of Biomedical Engineering , Seoul National University College of Medicine , Yongon-Dong, Seoul 110-799 , Korea.
Expert Rev Proteomics. 2017 Nov;14(11):963-971. doi: 10.1080/14789450.2017.1382356. Epub 2017 Oct 4.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide. However, there remain many unmet clinical needs, from diagnosis to treatment strategies. The inherent complexity of the molecular characteristics of PDAC has made it difficult to meet these challenges, rendering proteomic profiling of PDAC a critical area of research. Area covered: In this review, we present recent advances in mass spectrometry (MS) and its current application in proteomic studies on PDAC. In addition, we discuss future directions for research that can efficiently incorporate current MS-based technologies that address key issues of PDAC proteomics. Expert commentary: Compared with other cancer studies, little progress has been made in PDAC proteomics, perhaps attributed to the difficulty in performing in-depth and large-scale clinical studies on PDAC. However, recent advances in mass spectrometry can advance PDAC proteomics past the fundamental research stage.
胰腺导管腺癌（PDAC）是全球最致命的癌症之一。然而，从诊断到治疗策略，仍有许多未满足的临床需求。PDAC 分子特征的固有复杂性使得这些挑战难以应对，这使得 PDAC 的蛋白质组学分析成为一个关键的研究领域。
在这篇综述中，我们介绍了质谱（MS）的最新进展及其在 PDAC 蛋白质组学研究中的当前应用。此外，我们还讨论了未来的研究方向，以便有效地将当前基于 MS 的技术纳入解决 PDAC 蛋白质组学关键问题的研究中。
与其他癌症研究相比，PDAC 蛋白质组学的进展甚微，这可能归因于难以对 PDAC 进行深入和大规模的临床研究。然而，质谱的最新进展可以推动 PDAC 蛋白质组学超越基础研究阶段。
